Russell Investments Group
NVIV

Russell Investments Group’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Russell Investments Group’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2
Closed -$154K – 3114
2017
Q1 		$154K Hold
2
– – ﹤0.01% 2760
2016
Q4 		$162K Buy
+2
New +$179K ﹤0.01% 2761

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's NVIV Position: Q2 2017 in Review

Russell Investments Group sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2017, closing a stake of 2 shares — an estimated $154K sold.

Russell Investments Group first reported a position in NVIV in Q4 2016 and held it in 2 quarters. The position peaked at $162K in Q4 2016. 37 funds tracked by Wall St. Rank hold NVIV as of Q2 2017.

  • Russell Investments Group reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2017 after selling out during the quarter.
  • Russell Investments Group sold 2 InVivo Therapeutics Holdings Corp shares in Q2 2017, an estimated $154K.
  • Russell Investments Group first reported a position in InVivo Therapeutics Holdings Corp in Q4 2016 and held it in 2 quarters.
  • Russell Investments Group's InVivo Therapeutics Holdings Corp position peaked at $162K in Q4 2016.
  • 37 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2017.

Based on Russell Investments Group's 13F filing for Q2 2017, filed 25 Jul 2017.